Skip to main content

Rigel Pharmaceuticals Inc

RIGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001034842

No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Rigel Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Rigel Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Rigel Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Schorno Dean LEVP & Chief Financial Officer82,962Sep 3, 20267
Santos David AEVP, Chief Commercial Officer61,622Sep 3, 20266
Rodriguez Raul RCEO, President273,362Sep 3, 20266
Furey Raymond J.EVP, GC, CCO & Corp Sec50,559Sep 3, 20266
Hannah Alison L.EVP, Chief Medical Officer35,025Jul 10, 20262
Ali-Jackson KamilDirector10,125Jun 24, 20263
Rojkjaer LisaEVP, Chief Medical Officer34,003Jun 22, 20264
Moos Walter HDirector18,472May 19, 20262
Miller Michael PatrickDirector5,937May 19, 20262
Lapointe Anthony GreggDirector18,250May 19, 20261
Wasman JaneDirector18,250May 19, 20261
Frohlich Mark WDirector7,000May 19, 20261
Kotzin Brian L.Director100,000May 29, 20240
Lyons Gary ADirector75,000Jul 12, 20230
Dummer WolfgangEVP & CMO72,459Feb 6, 20230
Vance DollyEVP Corp. Affairs, G.C., Sect.60,260Sep 16, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 24, 2026 (view filing)Jun 222 daysAli-Jackson KamilDirectorSSale−2.50K$35.00−$87.5K−19.8%10.1K after10b5-1
May 28, 2026 (view filing)May 262 daysAli-Jackson KamilDirectorSSale−2.50K$29.17−$72.9K−16.5%12.6K after10b5-1
Feb 24, 2026 (view filing)Feb 204 daysMoos Walter HDirectorSSale−4.00K$36.36−$145.4K−23.9%12.7K after
Feb 6, 2025 (view filing)Feb 4-52 daysSchorno Dean LEVP & Chief Financial OfficerSSale−3.77K$21.38−$80.6K−6.2%57.2K after2 lots
Feb 6, 2025 (view filing)Feb 4-52 daysSantos David AEVP, Chief Commercial OfficerSSale−3.92K$21.38−$83.8K−7.0%51.7K after2 lots
Feb 6, 2025 (view filing)Feb 4-52 daysRodriguez Raul RCEO, PresidentSSale−9.35K$21.40−$200.1K−3.8%239.5K after2 lots
Feb 6, 2025 (view filing)Feb 4-52 daysFurey Raymond J.EVP, GC, CCO & Corp SecSSale−2.79K$21.41−$59.7K−6.7%38.8K after2 lots
Feb 6, 2024 (view filing)Feb 2-54 daysSantos David AEVP, Chief Commercial OfficerSSale−14.5K$1.14−$16.5K−4.0%349.1K after2 lots
Feb 6, 2024 (view filing)Feb 2-54 daysSchorno Dean LEVP & Chief Financial OfficerSSale−12.6K$1.14−$14.3K−3.0%402.9K after2 lots
Feb 6, 2024 (view filing)Feb 2-54 daysRodriguez Raul RCEO, PresidentSSale−52.9K$1.14−$60.1K−2.5%2.04M after2 lots
Feb 7, 2023 (view filing)Feb 61 dayRodriguez Raul RCEO, PresidentSSale−20.3K$1.75−$35.6K−1.2%1.68M after
Feb 6, 2023 (view filing)Feb 24 daysSantos David AEVP, Chief Commercial OfficerSSale−5.39K$1.66−$8.94K−3.6%144.6K after
Feb 6, 2023 (view filing)Feb 24 daysSchorno Dean LEVP & Chief Financial OfficerSSale−5.39K$1.66−$8.95K−2.7%196.5K after
Feb 6, 2023 (view filing)Feb 24 daysDummer WolfgangEVP & CMOSSale−5.39K$1.66−$8.95K−6.9%72.5K after
Jun 13, 2022 (view filing)Jun 94 daysRodriguez Raul RCEO, PresidentPPurchase+1.00M$0.69+$690.0K+255.2%1.39M after